Chinook Therapeutics Inc Revenue Growth Rates (KDNY), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Chinook Therapeutics Inc   (NASDAQ: KDNY)
 

KDNY's Revenue Growth by Quarter and Year

Chinook Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KDNY Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September -
2nd Quarter June 1.01
1st Quarter March 1.83
FY 2.84

KDNYs Annual Revenue
Chinook Therapeutics Inc 's Revenue in the fiscal year 2022 $ 6.13 millions
Chinook Therapeutics Inc 's Revenue in the fiscal year 2021 $ 51.63 millions
Chinook Therapeutics Inc 's Revenue in the fiscal year 2020 $ 0.83 millions
Chinook Therapeutics Inc 's Revenue in the fiscal year 2019 $ 17.26 millions
Chinook Therapeutics Inc 's Revenue in the fiscal year 2018 $ 15.09 millions




KDNY Revenue second quarter 2023 Y/Y Growth Comment
Chinook Therapeutics Inc reported Revenue surge of 140% year on year in the second quarter 2023, to $ 1.01 millions, this is lower than Chinook Therapeutics Inc 's recent average Revenue surge of 2295.14%.

Looking into second quarter 2023 results within Major Pharmaceutical Preparations industry 44 other companies have achieved higher Revenue growth. While Chinook Therapeutics Inc ' s Revenue doubling of 140% ranks overall at the positon no. 203 in the second quarter 2023.


KDNY Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - -99 % - -
3rd Quarter September - - - -21.04 %
2nd Quarter June 140 % 1300 % -99.46 % 13.91 %
1st Quarter March -32.22 % 671.43 % -97.49 % 254.06 %
FY   - -88.12 % 6119.28 % -

Financial Statements
Chinook Therapeutics Inc 's second quarter 2023 Revenue $ 1.01 millions KDNY's Income Statement
Chinook Therapeutics Inc 's second quarter 2022 Revenue $ 0.42 millions Quarterly KDNY's Income Statement


KDNY Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - -79.6 % - -
3rd Quarter September - 495.24 % - -31.96 %
2nd Quarter June -44.92 % -84.44 % -91.43 % -60.07 %
1st Quarter March 258.82 % -94.73 % - 284.3 %
FY (Year on Year)   - -88.12 % 6119.28 % -


Back to KDNY Growth rate Comparisons >> Back to KDNY Growth rate Comparisons >>


Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #45
Healthcare Sector #69
Overall #203

Revenue Y/Y Growth Statistics
High Average Low
62425 % 2295.14 % -99.89 %
(Sep 30 2022)   (Sep 30 2021)
Revenue second quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #45
Healthcare Sector #69
Overall #203
Revenue Y/Y Growth Statistics
High Average Low
62425 % 2295.14 % -99.89 %
(Sep 30 2022)   (Sep 30 2021)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Chinook Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1280800 % 41361.71 % -94.74 %
(Dec 31 2021)  


KDNY's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2023 Chinook Therapeutics Inc disclosed fall in Revenue from the first quarter by -44.92% to $ 1.01 millions, from $ 1.83 millions achived in the previous reporting period.

But that's not important problem, as Chinook Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 76 other companies have achieved higher Revenue quarter on quarter growth. While Chinook Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 1787.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #77
Healthcare Sector #227
Overall #1787
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #77
Healthcare Sector #227
Overall #1787
Revenue Q/Q Growth Statistics
High Average Low
1280800 % 41361.71 % -94.74 %
(Dec 31 2021)  


KDNY's II. Quarter Q/Q Revenue Comment
In the II. Quarter 2023 Chinook Therapeutics Inc disclosed fall in Revenue from the first quarter by -44.92% to $ 1.01 millions, from $ 1.83 millions achived in the previous reporting period.

But that's not important problem, as Chinook Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 76 other companies have achieved higher Revenue quarter on quarter growth. While Chinook Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 1787.


Chinook Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)
Cumulative Revenue 12 Months Ending $ 5.85 $ 5.26 $ 6.13 $ 56.85 $ 54.36
Y / Y Revenue Growth (TTM) -89.24 % -90.26 % -88.13 % - -
Year on Year Revenue Growth Overall Ranking # 3802 # 2813 # 4 # 0 # 8
Seqeuential Revenue Change (TTM) 11.22 % -14.18 % -89.22 % 4.59 % 0.71 %
Seq. Revenue Growth (TTM) Overall Ranking # 2481 # 1755 # 1586 # 980 # 2157


Cumulative Revenue growth Comment
Chinook Therapeutics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2023. If the fiscal year would end in Jun 30 2023, Chinook Therapeutics Inc 's annual Revenue improvement would be -89.24% year on year to $6 millions.

In the Healthcare sector 577 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2813 to 3802.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 137
Healthcare Sector # 578
Overall # 3802

Revenue TTM Y/Y Growth Statistics
High Average Low
6142.44 %
 215 %
-182 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 137
Sector # 372
S&P 500 # 2481
Cumulative Revenue growth Comment
Chinook Therapeutics Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Mar 31 2023. If the fiscal year would end in Jun 30 2023, Chinook Therapeutics Inc 's annual Revenue drop would be -89.24% year on year to $6 millions.

In the Healthcare sector 577 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2813 to 3802.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 137
Healthcare Sector # 578
Overall # 3802

Revenue TTM Y/Y Growth Statistics
High Average Low
6142.44 %
215 %
-182 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 137
Sector # 372
S&P 500 # 2481




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
KDNY's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Jun 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2023
Marinus Pharmaceuticals Inc 239.72%$ 239.721 millions
Cardiff Oncology Inc 237.50%$ 237.500 millions
Absci Corp236.03%$ 236.028 millions
Rosecliff Acquisition Corp I223.52%$ 223.516 millions
Anavex Life Sciences Corp 214.15%$ 214.150 millions
Kineta Inc 211.47%$ 211.467 millions
Prothena Corporation Public Limited Company206.33%$ 206.326 millions
Marizyme Inc 198.89%$ 198.887 millions
Inmune Bio Inc 187.50%$ 187.500 millions
Anaptysbio Inc 184.54%$ 184.539 millions
Avricore Health Inc 181.54%$ 181.542 millions
2seventy Bio Inc 167.38%$ 167.379 millions
Clearside Biomedical Inc 165.10%$ 165.104 millions
Kiniksa Pharmaceuticals International Plc164.99%$ 164.990 millions
Igc Pharma Inc 161.79%$ 161.792 millions
Bicycle Therapeutics Plc160.32%$ 160.324 millions
Mannkind Corporation157.28%$ 157.283 millions
Transmedics Group Inc 155.66%$ 155.665 millions
Mirati Therapeutics Inc 155.32%$ 155.315 millions
Tango Therapeutics Inc 152.95%$ 152.954 millions
Emmaus Life Sciences Inc 150.97%$ 150.968 millions
Mersana Therapeutics inc 148.69%$ 148.693 millions
Evoke Pharma Inc 144.99%$ 144.994 millions
Agile Therapeutics Inc144.40%$ 144.403 millions
Harpoon Therapeutics Inc 143.54%$ 143.538 millions
Chinook Therapeutics Inc 141.15%$ 141.148 millions
Ensysce Biosciences Inc 136.41%$ 136.405 millions
Novavax inc 128.28%$ 128.278 millions
Orchestra Biomed Holdings Inc 128.18%$ 128.180 millions
Impel Pharmaceuticals Inc 127.04%$ 127.042 millions


About Chinook Therapeutics Inc Revenue Growth Rates (KDNY), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Chinook Therapeutics Inc (CIK 1435049).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000950170-23-039041
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Chinook Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.